Compare FATE & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FATE | NHS |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.0M | 251.6M |
| IPO Year | 2013 | N/A |
| Metric | FATE | NHS |
|---|---|---|
| Price | $1.29 | $5.53 |
| Analyst Decision | Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $5.72 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 258.4K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.44% |
| EPS Growth | ★ 29.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $5.26 |
| 52 Week High | $3.23 | $7.75 |
| Indicator | FATE | NHS |
|---|---|---|
| Relative Strength Index (RSI) | 23.18 | 50.13 |
| Support Level | $1.07 | $5.26 |
| Resistance Level | $1.38 | $6.12 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 7.35 | 56.06 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.